Literature DB >> 10916591

Evaluating the costs of alternative options for dementia services.

T J Chaussalet1, P H Millard, E el-Darzi.   

Abstract

In the next decade the number of demented people is likely to increase. This has a financial impact on the resources allocated for health and social care. Classical methodologies for dealing with dementia include the historic model that has been criticised for its poor co-ordination between general practitioners, psychiatrists, social workers and the treatment services, and the needs-based approach that, although it involves a co-ordinating needs manager, does not prevent leapfrogging of patients. In order to overcome these problems we propose an annual screening of patients to take place in the needs-based models and compare this with a more sophisticated model in which after being screened patients are investigated for potential drug treatment. We also consider mix intervals for under 75 and over 75. Decision analysis is used to assess the different screening options. Assuming a 20% reduction by treatment of the cost of care we find optimal the investigation/treatment of all patients after screening. Sensitivity analysis shows that even an 8.5% reduction would make the needs-based models non-optimal.

Entities:  

Mesh:

Year:  1998        PMID: 10916591     DOI: 10.1023/a:1019007005290

Source DB:  PubMed          Journal:  Health Care Manag Sci        ISSN: 1386-9620


  6 in total

1.  Tacrine for Alzheimer's disease. Costs and benefits.

Authors:  D Knopman
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 2.  The mini-mental state examination: a comprehensive review.

Authors:  T N Tombaugh; N J McIntyre
Journal:  J Am Geriatr Soc       Date:  1992-09       Impact factor: 5.562

3.  Treating Alzheimer's disease. Pharmacologic options now and in the near future.

Authors:  P N Tariot; L Schneider; A P Porsteinsson
Journal:  Postgrad Med       Date:  1997-06       Impact factor: 3.840

4.  Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group.

Authors:  D Knopman; L Schneider; K Davis; S Talwalker; F Smith; T Hoover; S Gracon
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

5.  The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group.

Authors:  A Hofman; W A Rocca; C Brayne; M M Breteler; M Clarke; B Cooper; J R Copeland; J F Dartigues; A da Silva Droux; O Hagnell
Journal:  Int J Epidemiol       Date:  1991-09       Impact factor: 7.196

6.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

Authors:  M Farlow; S I Gracon; L A Hershey; K W Lewis; C H Sadowsky; J Dolan-Ureno
Journal:  JAMA       Date:  1992-11-11       Impact factor: 56.272

  6 in total
  2 in total

Review 1.  Health care modelling and clinical practice. Theoretical exercise or practical tool?

Authors:  D G Seymour
Journal:  Health Care Manag Sci       Date:  2001-02

2.  Data requirements in a model of the natural history of Alzheimer's disease.

Authors:  T J Chaussalet; W A Thompson
Journal:  Health Care Manag Sci       Date:  2001-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.